UNITEDHEALTH GROUP INC. : Collaborations, New Studies, and New Drug ... 4-traders (press release) Gilead also informed that along with this NDA, the Company submitted data that supports the use of idelalisib for patients with iNHL that is refractory (non-responsive) to rituximab and to alkylating-agent-containing chemotherapy. The Company further ... |
